Antofagasta plc (LON:ANTO – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is GBX 2,454.17.
A number of brokerages have weighed in on ANTO. Royal Bank Of Canada restated a “sector perform” rating and issued a GBX 1,900 target price on shares of Antofagasta in a research note on Friday, October 10th. JPMorgan Chase & Co. upped their target price on Antofagasta from GBX 2,500 to GBX 3,500 and gave the stock an “overweight” rating in a research note on Friday, October 10th. Berenberg Bank increased their price objective on Antofagasta from GBX 2,200 to GBX 2,900 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft increased their price objective on Antofagasta from GBX 1,950 to GBX 2,000 and gave the company a “hold” rating in a research report on Monday, August 4th. Finally, Citigroup reiterated a “buy” rating and set a GBX 2,300 price objective on shares of Antofagasta in a research report on Friday, August 15th.
Check Out Our Latest Stock Report on ANTO
Antofagasta Price Performance
About Antofagasta
Antofagasta plc is a copper mining group with significant by-product production and interests in transportation. The Group creates value for its stakeholders through the discovery, development and operation of copper mines. The Group is committed to generating value in a safe and sustainable way throughout the commodity cycle.
Featured Stories
- Five stocks we like better than Antofagasta
- Upcoming IPO Stock Lockup Period, Explained
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- What is the Shanghai Stock Exchange Composite Index?
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Buy P&G Now, Before It Sets A New All-Time High
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Antofagasta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antofagasta and related companies with MarketBeat.com's FREE daily email newsletter.